Dual-task assessment in natalizumab-treated multiple sclerosis patients.
Details
Serval ID
serval:BIB_E652C596CEAF
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Dual-task assessment in natalizumab-treated multiple sclerosis patients.
Journal
European neurology
ISSN
1421-9913 (Electronic)
ISSN-L
0014-3022
Publication state
Published
Issued date
2014
Peer-reviewed
Oui
Volume
71
Number
5-6
Pages
247-251
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Abstract
To study the 1-year evolution of quantitative dual-task gait parameters in comparison with single-task gait parameters and detailed neuropsychological assessment in patients with multiple sclerosis (MS) treated with natalizumab.
Walking speed, stride length and stride time during a dual task (walking while forward counting, backward counting, semantic fluency, and phonemic fluency), a single walking task, and a detailed neuropsychological assessment were prospectively measured and assessed twice at the 1-year interval in 9 consecutive patients with MS treated with natalizumab.
Dual-task-related gait changes (walking speed, stride length and stride time while performing semantic fluency and walking speed, and stride time while performing phonemic fluency) showed a significant improvement after 1 year of treatment with natalizumab. The single walking task and detailed neuropsychological assessment did not present any modification.
Dual-task-related gait changes using a cognitive task with a specific executive demand represent an interesting marker of disease-modifying therapy in patients with MS.
Walking speed, stride length and stride time during a dual task (walking while forward counting, backward counting, semantic fluency, and phonemic fluency), a single walking task, and a detailed neuropsychological assessment were prospectively measured and assessed twice at the 1-year interval in 9 consecutive patients with MS treated with natalizumab.
Dual-task-related gait changes (walking speed, stride length and stride time while performing semantic fluency and walking speed, and stride time while performing phonemic fluency) showed a significant improvement after 1 year of treatment with natalizumab. The single walking task and detailed neuropsychological assessment did not present any modification.
Dual-task-related gait changes using a cognitive task with a specific executive demand represent an interesting marker of disease-modifying therapy in patients with MS.
Keywords
Adult, Antibodies, Monoclonal, Humanized/therapeutic use, Biomechanical Phenomena, Cognition/drug effects, Cognition/physiology, Executive Function/drug effects, Executive Function/physiology, Female, Follow-Up Studies, Gait/drug effects, Gait/physiology, Humans, Immunologic Factors/therapeutic use, Male, Multiple Sclerosis, Relapsing-Remitting/drug therapy, Multiple Sclerosis, Relapsing-Remitting/physiopathology, Multiple Sclerosis, Relapsing-Remitting/psychology, Natalizumab, Neuropsychological Tests, Prospective Studies, Psychomotor Performance/drug effects, Psychomotor Performance/physiology, Treatment Outcome, Walking/physiology
Pubmed
Web of science
Create date
06/10/2023 8:17
Last modification date
07/10/2023 5:58
Usage data
